GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Has Consensus Target Price of $4.15

GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) has been given an average rating of “Hold” by the thirteen research firms that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $4.15.

A number of research firms recently issued reports on GDRX. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of GoodRx in a research note on Wednesday, November 4th. Citigroup raised their price target on GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Barclays boosted their price target on GoodRx from $3.00 to $4.00 and gave the stock an “underweight” rating in a report on Thursday, August 20th. UBS Group boosted their price target on GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a report on Thursday, August 13th. Finally, Leerink Partners set a $5.00 price objective on GoodRx in a research report on Thursday, August 6th.

Read Our Latest Analysis on GDRX

Insider Buying and Selling

In other GoodRx news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 1,567,044 shares of company stock worth $5,471,274. Company insiders own 5.87% of the company’s stock.

Institutional Investors Weigh In On GoodRx

Hedge funds and other institutional investors have recently modified their holdings of the company. Technology Crossover Management X Ltd. acquired a new position in shares of GoodRx in the second quarter valued at approximately $4,762,000. Algert Global LLC purchased a new position in shares of GoodRx during the third quarter valued at approximately $2,125,000. Marshall Wace LLP lifted its stake in shares of GoodRx by 72.1% during the third quarter. Marshall Wace LLP now owns 934,398 shares of the company’s stock valued at $3,074,000 after buying an additional 391,370 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of GoodRx during the second quarter valued at approximately $540,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in GoodRx during the second quarter worth approximately $500,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Trading Down 3.3%

Shares of GDRX opened at $2.92 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The firm has a 50 day simple moving average of $3.43 and a 200-day simple moving average of $2.89. GoodRx has a 1-year low of $1.77 and a 1-year high of $3.89. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of 73.02 and a beta of 1.66.

GoodRx Company Profile

(Get Free Report)

GoodRx Holdings, Inc. operates a digital healthcare platform that helps consumers in the United States compare prescription medication prices at pharmacies. Its website and mobile app provide free price comparisons and discounts that consumers can use when paying for eligible prescriptions. The company also offers subscription services, including GoodRx Gold, and provides access to telehealth and other care services through GoodRx Care. Its platform connects consumers with pharmacies and healthcare providers, while its services for pharmaceutical companies include programs that help make medications and savings offers available to patients.

Recommended Stories

Analyst Recommendations for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.